Zafirlukast (107753-78-6) is a competitive and selective leukotriene receptor antagonist1. Also inhibits calcium ionophore induced production of leukotriene B4 and leukotriene C4, which suggests a potential 5-LO inhibitory activity2. Cell permeable and orally active.
1) Adkins and Brogden, (1998), Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma; Drugs, 55 121
2) Woszczek et al., (2010), Concentration-dependent noncysteinyl leukotriene type 1 receptor-mediated inhibitory activity of leukotriene receptor antagonists; J. Immunol. 184 2218
3) Wyttenbach & Kuentz (2017), Glass-forming ability of compounds in marketed amorphous drug products; Eur. J. Pharm. and Biopharm., 112 204 [Focus Citation]